Patents Issued in April 14, 2022
  • Publication number: 20220112186
    Abstract: Disclosed herein are a process for preparing alkynyl-containing compound and intermediate thereof.
    Type: Application
    Filed: February 26, 2020
    Publication date: April 14, 2022
    Inventors: Ming Guo, Jianfeng Wen, Shangjun Teng, Tianzhu Wu, Jianpeng Feng
  • Publication number: 20220112187
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and X are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 11, 2018
    Publication date: April 14, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Haixia LIU, Hong SHEN, Wei ZHU, Taishan HU, Zhiwei ZHANG, Fabian DEY
  • Publication number: 20220112188
    Abstract: The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis.
    Type: Application
    Filed: January 11, 2020
    Publication date: April 14, 2022
    Inventors: Xiaohu Zhang, Sudan He, Haikuo MA
  • Publication number: 20220112189
    Abstract: The invention relates to compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of cryptosporidiosis by administering such a compound.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 14, 2022
    Inventors: Joseph Michael Young, Michael Robert Turner, Peichao Lu
  • Publication number: 20220112190
    Abstract: The present disclosure relates to salts and crystalline forms of a compound having the formula: Also described are processes for the production of the salts and crystalline forms described herein.
    Type: Application
    Filed: October 25, 2021
    Publication date: April 14, 2022
    Inventors: Chaoyi Deng, Jun He, Bo Xu
  • Publication number: 20220112191
    Abstract: The present application provides bifunctional compounds of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 8 (CDK8). The present application also relates to methods for the targeted degradation of CDK8 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK8 which can be utilized in the treatment of disorders modulated by CDK8.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Calla M. Olson, Yanke Liang, Nicholas Kwiatkowski
  • Publication number: 20220112192
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein A, B, R1, R3, L1, L2, L3, E, A1, A2, A3, A4, G1, G2, W, X, Y, Z, m1, m2, n1, and n2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: November 27, 2019
    Publication date: April 14, 2022
    Inventors: Liansheng LI, Yuan LIU, Tao WU, Pingda REN, Yi LIU
  • Publication number: 20220112193
    Abstract: Described herein are crystalline forms of (R)—N-(1-(4-aminobenzyl)-1H-pyrazol-4-yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido[3?,2?:4,5]-pyrrolo[1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia.
    Type: Application
    Filed: February 10, 2020
    Publication date: April 14, 2022
    Inventors: Richard WINNIKE, Elaine MCPHERSON, Erik FLAHIVE, Sandra E. DUNN, Jonathan LOUGHREY
  • Publication number: 20220112194
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 30, 2021
    Publication date: April 14, 2022
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing, Francois Gonzalvez
  • Publication number: 20220112195
    Abstract: The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of Gram-positive bacteria infections.
    Type: Application
    Filed: April 2, 2021
    Publication date: April 14, 2022
    Inventors: Xiang Y. YU, Li H. XING, Minghua WANG, Casey McCOMAS, Michael SILVERMAN, Richard SOLL
  • Publication number: 20220112196
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 24, 2021
    Publication date: April 14, 2022
    Inventors: Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
  • Publication number: 20220112197
    Abstract: The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals. In some embodiments, the present disclosure provides a compound of Formula (I) or tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer.
    Type: Application
    Filed: August 23, 2021
    Publication date: April 14, 2022
    Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Zoltan F. Kanyo, Joseph A. Ippolito
  • Publication number: 20220112198
    Abstract: The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: October 27, 2021
    Publication date: April 14, 2022
    Inventors: Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Daniel Levy, Eddy W. Yue
  • Publication number: 20220112199
    Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Publication number: 20220112200
    Abstract: Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Xiangyang Chen, Yucheng Pang
  • Publication number: 20220112201
    Abstract: Disclosed are macrocyclic compounds that possess inhibitory activity against DYRK, TRK, TLK, and/or RET. Also disclosed are pharmaceutical compositions containing the compounds, methods of making the compounds, and methods of using the compounds to treat diseases and disorders that are characterized or mediated by aberrant DYRK, TRK, TLK, and/or RET activity such as cancer, neurodegenerative disorders and genetic disorders.
    Type: Application
    Filed: November 19, 2019
    Publication date: April 14, 2022
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., VORONOI INC.
    Inventors: Nathanael S. Gray, John M. Hatcher, Hwangeun Choi
  • Publication number: 20220112202
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Jens WILLWACHER
  • Publication number: 20220112203
    Abstract: Disclosed are novel compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.
    Type: Application
    Filed: May 3, 2021
    Publication date: April 14, 2022
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Michelle Richter, Andrew Riley, Bryon S. Drown, Martin Chavez, Sarah Tasker, Alfredo Garcia
  • Publication number: 20220112204
    Abstract: The present disclosure relates to novel compounds that inhibit KRAS G120, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Applicant: ACCUTAR BIOTECHNOLOGY INC.
    Inventors: Jie FAN, Yimin QIAN, Wei HE, Robert Z. LUO
  • Publication number: 20220112205
    Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
    Type: Application
    Filed: September 24, 2021
    Publication date: April 14, 2022
    Inventors: Solomon B. Ungashe, Stephen D. Yanofsky
  • Publication number: 20220112206
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. SCHAUS, Ulla HANSEN, John A. KAVOURIS, Emily A. YORK, Niranjana POKHAREL
  • Publication number: 20220112207
    Abstract: A method for the synthesis of diazabicyclo[6.2.0]decane compounds is provided. The synthesis proceeds by stereoselective synthesis of a chiral lactone followed by azetidine formation via a series of chemoselective reactions. Bicyclization results with the formation of diazobicyclo[6.2.0]decane related compounds.
    Type: Application
    Filed: January 9, 2020
    Publication date: April 14, 2022
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. FANG, Branko MITASEV, Jiong YANG
  • Publication number: 20220112208
    Abstract: Compounds with anti-inflammatory activity, methods of extracting and isolating the compounds from seaweed, and methods of using the compounds are disclosed herein. The compounds can be extracted and isolated from seaweed, such as Laurencia. Typically, the compound disclosed herein has anti-inflammatory activity with negligible toxicity, and thus can be used as anti-inflammatory agents.
    Type: Application
    Filed: October 8, 2021
    Publication date: April 14, 2022
    Inventors: Carlos M. Duarte, Susana Agusti, Mariusz Jaremko, Lukasz Jaremko, Vaileios Roussis, Efstathia Ioannou, Aikaterini Koutsaviti, Christos Tsatsanis, Sotirios Kampranis, Maria Daskalaki
  • Publication number: 20220112209
    Abstract: A tetracarboxylic dianhydride that is a mixture of stereoisomers of a compound represented by the following general formula (1): [in the formula (1), R1, R2, and R3 each independently represent a hydrogen atom or the like and n is an integer of 0 to 12], wherein a content of an isomer (A) represented by a specific general formula is 40% by mol to 98% by mol relative to a total amount of the stereoisomers, a content of an isomer (B) represented by a specific general formula is 2% by mol to 60% by mol relative to the total amount of the stereoisomers, and a summed amount of the isomers (A) and (B) is 42% by mol or more relative to the total amount of the stereoisomers.
    Type: Application
    Filed: August 1, 2019
    Publication date: April 14, 2022
    Applicant: ENEOS CORPORATION
    Inventors: Shinichi KOMATSU, Daisuke WATANABE
  • Publication number: 20220112210
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Inventors: Florian Paul Christian BINDER, Thomas Martin FLECK, Jens WILLWACHER
  • Publication number: 20220112211
    Abstract: The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 14, 2022
    Inventors: Craig M. CREWS, George BURSLEM, Philipp M. CROMM, Saul JAIME-FIGUEROA, Momar TOURE
  • Publication number: 20220112212
    Abstract: The present invention relates to novel crystalline polymorphs of sodium (4R,12aS)-9-{[(2,4-difluorophenyl) methyl] carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1?,2?:4,5] pyrazino[2,1-b] [1,3] oxazin-7-olate represented by the following structural formula-1a and process for their preparation. The present invention further relates to novel solvated forms of sodium (4R,12aS)-9-{[(2,4-difluoro phenyl) methyl] carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1?,2?:4,5] pyrazino[2,1-b][1,3] oxazin-7-olate compound of formula-1a and process for their preparation.
    Type: Application
    Filed: February 4, 2020
    Publication date: April 14, 2022
    Applicant: MSN LABORATORIES PRIVATE LIMITED, R&D CENTER
    Inventors: Thirumalai Rajan SRINIVASAN, Eswaraiah SAJJA, Rajeshwar Reddy SAGYAM, Srinivasulu RAGINENI, Venkata Narasayya SALADI
  • Publication number: 20220112213
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Application
    Filed: September 27, 2021
    Publication date: April 14, 2022
    Inventors: Jingrong Jean CUI, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Publication number: 20220112214
    Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Application
    Filed: September 6, 2019
    Publication date: April 14, 2022
    Inventors: James F. BLAKE, Donghua DAI, Julia HAAS, Yutong JIANG, Dean KAHN, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Andrew T. METCALF, David A. MORENO, Brett PRIGARO, Ginelle A. RAMANN, Li REN, Shane M. WALLS, Hailong ZHANG
  • Publication number: 20220112215
    Abstract: A compound is described as having a triplet excited state and a singlet excited state; wherein the triplet excited state comprises a lowest energy triplet sublevel, a middle energy triplet sublevel, and a highest energy triplet sublevel; and wherein an energy separation between the highest energy triplet sublevel and the lowest energy triplet sublevel (ZFS) is greater than an energy separation between the singlet excited state and a the lowest energy triplet sublevel. Also described is a compound represented by the following Formula I. These compounds should find application as luminescent materials in organic light emitting diodes (OLEDs).
    Type: Application
    Filed: September 22, 2021
    Publication date: April 14, 2022
    Inventors: Mark E. THOMPSON, Peter I. DJUROVICH
  • Publication number: 20220112216
    Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
    Type: Application
    Filed: October 22, 2021
    Publication date: April 14, 2022
    Applicants: The Broad Institute, Inc., Biogen MA Inc.
    Inventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Edward Holson, Brian Stuart Lucas, TeYu Chen
  • Publication number: 20220112217
    Abstract: A series of pyrazolopyrimidine derivatives can be used in preparing a medicament for treating a disease related to PI3K. For example, a compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof are effective in treating a disease related to P13K.
    Type: Application
    Filed: August 21, 2019
    Publication date: April 14, 2022
    Inventors: Chengde WU, Jingjie HUANG, Tao YU, Jie LI, Zhen GONG, Jian LI, Shuhui CHEN
  • Publication number: 20220112218
    Abstract: This document provides methods and materials for increasing TFEB polypeptide levels. For example, compounds (e.g., organic compounds) having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for making formulations containing compounds having the ability to increase TFEB polypeptide levels within cells and/or within a nucleus of cells, methods for increasing TFEB polypeptide levels within cells and/or within a nucleus of cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in TFEB polypeptide levels are provided.
    Type: Application
    Filed: January 3, 2020
    Publication date: April 14, 2022
    Inventors: Beibei Chen, Toren Finkel, Yuan Liu
  • Publication number: 20220112219
    Abstract: The present disclosure provides processes for preparing a crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile and related intermediate compounds.
    Type: Application
    Filed: October 7, 2021
    Publication date: April 14, 2022
    Inventors: Norbert Kraut, Matteo Conza, Anja Huste, Vit Lellek, Bjorn Gielen, Christian Pater, Dimitar Filipov, Xiaojun Huang, Stephen Roseblade
  • Publication number: 20220112220
    Abstract: The present disclosure relates to pharmaceutical compositions comprising (3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile), methods of use thereof, and methods of preparation.
    Type: Application
    Filed: October 7, 2021
    Publication date: April 14, 2022
    Inventors: Bernardus Joseph Nitert, Yvonne Rosiaux, Marian E. Van Der Veen, Nathan Schulpen, Jens Maes, Guido Verniest, Venkat R. Thalladi, Ai Ling Ching
  • Publication number: 20220112221
    Abstract: The present disclosure relates to a novel organic compound and an organic electroluminescent device comprising the same, and more particularly, to an organic compound having excellent lifespan, efficiency, electrochemical stability, and thermal stability, and an organic electroluminescent device comprising the same.
    Type: Application
    Filed: November 17, 2021
    Publication date: April 14, 2022
    Inventors: Dong Hun LEE, Kwang Seok DO, Ji Woong YOO
  • Publication number: 20220112222
    Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.
    Type: Application
    Filed: November 22, 2021
    Publication date: April 14, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noriko Sato, Haitao Wu, Gary L. Griffiths, Peter L. Choyke
  • Publication number: 20220112223
    Abstract: A method of preparing an organosilanol compound is disclosed. The method comprises reacting (A) an initial organosilicon compound and (B) water in the presence of (C) a catalyst. The catalyst (C) is selected from: (C1) [(C8H12irCl]2[(p-cymene)RuCl2]2; and (C3) Pd/C. The initial organosilicon compound (A) has the general formula HO—Si(R)2—[Si(R)2O]a—OSi(R)2—Y and the organosilanol compound has the general formula HO—Si(R)2-[Si(R)2O]a—OSi(R)2—Y, where each R is an independently selected hydrocarbyl group; Y comprises a functional moiety selected from alkoxysilyl moieties, epoxide moieties, and acryloxy moieties, with the proviso that Y is other than the acryloxy moieties when the catalyst (C) is (C3) Pd/C; and subscript a is 0 or 1. The organosilanol compound prepared by the method is also provided.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 14, 2022
    Inventors: Donald V. ELDRED, Matthew JELETIC, John ROBERTS, Andre YVON-BESSETTE
  • Publication number: 20220112224
    Abstract: A branched organosilicon compound (“compound”) having the general formula (R1)3Si—X—Y is provided. In the formula: each R1 is selected from R and —OSi(R4)3, with the proviso that at least one R1 is —OSi(R4)3; each R is independently a substituted or unsubstituted hydrocarbyl group; each R4 is selected from R, —OSi(R5)3, and —[OSiR2]mOSiR3; each R5 is selected from R, —OSi(R6)3, and —[OSiR2]mOSiR3; each R6 is selected from R and —[OSiR2]mOSiR3; with the proviso that at least one of R4, R5 and R6 is —[OSiR2]mOSiR3; 0<m?100; X is a divalent linking group; and Y is selected from one of formulas (1)-(111) described herein. Also provided is a method of preparing the compound via hydrosilylation reaction, a copolymer comprising the reaction product of the compound and a second compound reactive with the compound, a method of forming the copolymer, and a composition including at least one of the compound and the copolymer.
    Type: Application
    Filed: December 27, 2019
    Publication date: April 14, 2022
    Inventors: Matthew JELETIC, Nanguo LIU
  • Publication number: 20220112225
    Abstract: The present application provides anandamide and 2-arachidonoyl glycerol compounds useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating diseases or disorders are also provided.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 14, 2022
    Inventors: David Lawrence Silver, Mahmood Ahmed, Sing Yeung Frankie Mak
  • Publication number: 20220112226
    Abstract: The present disclosure provides a composition including trifluoroacetyl iodide, at least one organic impurity and at least one inorganic impurity. The at least one organic impurity includes at least one of: difluoroiodomethane, pentafluoroiodoethane, iodomethane, iodopropane, dichlorotetrafluoroethane, dichlorotrifluoroethane, trichlorotrifluoroethane, methyltrifluoroacetate, trifluoroacetic anhydride, difluorobutane and methyl propane. The at least one inorganic impurity includes at least one of: hydrogen iodide, hydrogen chloride, iodine and hydrogen triiodide.
    Type: Application
    Filed: October 6, 2021
    Publication date: April 14, 2022
    Inventors: Haiyou Wang, Haridasan K. Nair, Daniel C. Merkel, Selma Bektesevic, Terris Yang
  • Publication number: 20220112227
    Abstract: The present invention relates to ligands based on calixarenes, metal complexes comprising such ligands and their use as homogeneous or heterogeneous catalysts.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Vincent Germain HUC, Cyril August Roger MARTINI, Ibrahim ABDELLAH, Emmanuelle SCHULZ
  • Publication number: 20220112228
    Abstract: Provided are organometallic compounds including a ligand LA of Formula I Also provided are formulations including these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.
    Type: Application
    Filed: September 16, 2021
    Publication date: April 14, 2022
    Applicant: UNIVERSAL DISPLAY CORPORATION
    Inventors: Zhiqiang JI, Wei-Chun SHIH, Pierre-Luc T. BOUDREAULT
  • Publication number: 20220112229
    Abstract: There is provided an organometallic compound represented by Formula 1 and an organic light-emitting device including the same: wherein, the detailed description of Formula 1 is the same as described in the present specification.
    Type: Application
    Filed: March 25, 2021
    Publication date: April 14, 2022
    Inventors: Hyunjung LEE, Soobyung KO, Sungbum KIM, Eunsoo AHN, Eunyoung LEE
  • Publication number: 20220112230
    Abstract: Preparation of n{circumflex over (?)}n{circumflex over (?)}c{circumflex over (?)}n tetradentate platinum (ii) complex and uses thereof are provided. The complex of the present invention has a structure as shown in Formula (11). The performance of an organic electroluminescence device prepared from the complex of the present invention is better than that of a reference device. A great application value is realized on an OLED (organic light-emitting diode), and the N{circumflex over (?)}N{circumflex over (?)}C{circumflex over (?)}N tetradentate platinum (II) complex can be used as a phosphorescent doped material to manufacture an orange red light OLED device with a high luminous efficiency.
    Type: Application
    Filed: November 2, 2019
    Publication date: April 14, 2022
    Applicant: GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD
    Inventors: Jian KANG, Lei DAI, Lifei CAI
  • Publication number: 20220112231
    Abstract: Provided is an organometallic compound, a light-emitting device including the same, and an electronic apparatus including the light-emitting device.
    Type: Application
    Filed: May 25, 2021
    Publication date: April 14, 2022
    Applicant: Samsung Display Co., Ltd.
    Inventors: Junghoon HAN, Soobyung KO, Sungbum KIM, Eunsoo AHN, Jaesung LEE, Hyunjung LEE
  • Publication number: 20220112232
    Abstract: Provided are organometallic compounds including a ligand LA of Also provided are formulations including these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.
    Type: Application
    Filed: September 17, 2021
    Publication date: April 14, 2022
    Applicant: UNIVERSAL DISPLAY CORPORATION
    Inventors: Morgan C. MACINNIS, Hsiao-Fan CHEN, Noah HORWITZ, Nicholas J. THOMPSON
  • Publication number: 20220112233
    Abstract: Provided are a method for producing a peptide compound including a step of using a condensed polycyclic aromatic hydrocarbon compound represented by Formula (1); a protective group-forming reagent including the compound; and the compound. In Formula (1), a ring A represents a condensed polycyclic aromatic hydrocarbon ring, YA's each independently represent —OH, —NHR, —SH, or —X0, where X0 represents Cl, Br, or I, RA and RC each independently represent an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group, RBs' each independently represent a monovalent aliphatic hydrocarbon group, a (1+c)-valent aromatic group, or a (1+c)-valent heteroaromatic group, where, in a case where both a and c is 0, RB is a monovalent aliphatic hydrocarbon group, and the number of carbon atoms in at least one aliphatic hydrocarbon group is 12 or more.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Yosuke YAMAMOTO, Kazuhei KANEKO, Hirofumi OMURA, Motomasa TAKAHASHI, Makoto TAKAHASHI
  • Publication number: 20220112234
    Abstract: Provided are a method for producing a peptide compound including a step of using a compound represented by Formula (1); a protective group-forming reagent including the compound; and the compound. At least one of R1 to R8 or Y2 has RA, RA represents an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group, and the number of carbon atoms in at least one aliphatic hydrocarbon group is 12 or more. However, RA does not have a silyl group and a hydrocarbon group having a silyloxy structure.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Yosuke YAMAMOTO, Makoto TAKAHASHI
  • Publication number: 20220112235
    Abstract: The present invention relates to a novel process for purifying phycocyanins produced by fermenting microalgae, in particular produced by Galdieria sulphuraria, which comprises an enzymatic degradation of glycogen.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 14, 2022
    Inventors: Olivier CAGNAC, Axel ATHANE, Julien DEMOL